Ziconotide
omega-conotoxin MVIIA, ω-conotoxin MVIIA, SNX-111, CI-1009
Ziconotide is a synthetic copy of a 25-amino-acid toxin from the venom of the marine cone snail Conus magus. It blocks N-type calcium channels on pain-transmitting nerve terminals in the spinal cord and is delivered directly into the cerebrospinal fluid via an implanted pump. It is a genuinely non-opioid analgesic (no tolerance, no dependence, no respiratory depression), but its neuropsychiatric side effects and narrow therapeutic window confine it to severe refractory pain.
Mechanism
Ziconotide is chemically identical to ω-conotoxin MVIIA, one of the paralytic peptides that Conus magus, a fish-hunting cone snail, injects into prey. It adopts the inhibitor cystine knot (knottin) fold: 25 residues braced by three disulfide bridges (Cys1-Cys16, Cys8-Cys20, Cys15-Cys25) in a threaded arrangement that makes the molecule extraordinarily rigid and resistant to denaturation.
Its target is the N-type voltage-gated calcium channel, Cav2.2, which is densely expressed on the presynaptic terminals of primary nociceptive afferents in laminae I and II of the dorsal horn. Depolarisation of these terminals normally opens Cav2.2, and the resulting calcium influx triggers vesicular release of substance P, calcitonin gene-related peptide and glutamate onto second-order neurons. Ziconotide binds Cav2.2 with high affinity and selectivity and blocks that calcium entry, so the neurotransmitters are never released and nociceptive signalling is interrupted at its first synapse.
Two consequences follow directly. First, because the mechanism is entirely independent of opioid receptors, ziconotide produces no tolerance, no physical dependence, no withdrawal syndrome and no respiratory depression, and it remains effective in patients who have exhausted opioid options. Second, it must be given intrathecally. N-type channels also serve sympathetic postganglionic neurons, so systemic administration causes severe hypotension; the peptide does not cross the blood-brain barrier in useful quantities and is rapidly degraded outside the cerebrospinal fluid. Delivery therefore requires an implanted or external intrathecal pump, and the drug is cleared from cerebrospinal fluid into plasma with a terminal half-life of about 4.6 hours.
What the research shows
The pivotal efficacy trial (Staats and colleagues, 2004) randomised 111 patients with refractory pain from cancer or AIDS to intrathecal ziconotide or placebo (68 ziconotide, 40 placebo, with a subsequent crossover phase). Mean pain scores improved by 53.1% (95% CI 44.0-62.2%) with ziconotide versus 18.1% (95% CI 4.8-31.4%) with placebo, and 52.9% of ziconotide patients versus 17.5% of placebo patients achieved moderate to complete pain relief (p<0.001). These are large effects, but the rapid titration used in this and a companion trial in non-malignant pain produced a heavy burden of adverse events.
The trial that shaped actual clinical practice was Rauck and colleagues (2006), which tested slow titration in 220 patients with severe chronic pain (112 ziconotide, 108 placebo). Starting at 0.1 µg/hour and increasing gradually over three weeks to a mean of 0.29 µg/hour, ziconotide produced a mean pain improvement of 14.7% versus 7.2% with placebo at week 3. The efficacy signal was far smaller than in the rapid-titration studies, but tolerability was much better and discontinuation rates were comparable between groups. The authors concluded that slow titration to a low maximum dose gave significant pain improvement and was better tolerated than in the two previous controlled trials. This trade-off, smaller but real analgesia in exchange for manageable side effects, defines how ziconotide is used.
Longer-term open-label extension data support sustained analgesia over months to years without dose escalation, which is the practical expression of the absence of tolerance. Preclinical and pilot work has explored other applications, but these remain preclinical.
Evidence assessment
High-quality evidence
Ziconotide holds FDA (December 2004), EMA (February 2005) and MHRA marketing authorisations for severe chronic pain requiring intrathecal analgesia, granted on the basis of three randomised double-blind placebo-controlled trials in malignant and non-malignant pain. The two cited here were verified against PubMed with matching titles, PMIDs, DOIs, journals, years, sample sizes and effect estimates. That is replicated randomised evidence plus regulator-approved labelling. The caveats are about magnitude and tolerability rather than existence: the slow-titration trial that established the usable dosing approach produced a mean pain improvement of 14.7% versus 7.2% for placebo (statistically significant but modest), and the neuropsychiatric adverse effect burden is substantial.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial Preclinical only
Mean pain scores improved by 53.1% (95% CI 44.0-62.2%) with ziconotide versus 18.1% (95% CI 4.8-31.4%) with placebo. Moderate to complete pain relief was achieved by 52.9% versus 17.5% of patients (p<0.001). The authors concluded the drug provided clinically and statistically significant analgesia.
A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain Preclinical only
Mean pain improvement was 14.7% with ziconotide versus 7.2% with placebo at week 3, a modest but significant effect. Adverse events included dizziness, confusion, ataxia and memory impairment, but discontinuation rates were comparable between groups, and tolerability was markedly better than in the two earlier rapid-titration trials.
Safety
The safety profile is dominated by neuropsychiatric effects and is the reason the drug carries a boxed warning in the US. Severe psychiatric symptoms (confusion, hallucinations, paranoid reactions, psychosis, depression, and both suicidal ideation and completed suicide) have been reported, and pre-existing psychosis is a contraindication. Cognitive impairment, memory loss, speech disorder, somnolence and reduced alertness can develop gradually over weeks and may take a fortnight or more to resolve after stopping. Neurological effects include dizziness, ataxia, nystagmus, gait disturbance and abnormal vision.
Elevated creatine kinase is common and has occasionally been associated with rhabdomyolysis. Nausea, vomiting, urinary retention, hypotension and peripheral oedema are reported. Meningitis is a risk of the intrathecal delivery system rather than the drug, but it is a real and potentially fatal complication of any implanted pump, as are catheter granuloma and pump malfunction.
The therapeutic index is narrow and the drug is titrated very slowly against symptoms with regular cognitive and psychiatric assessment. Ziconotide is emphatically not an alternative to opioids in ordinary practice: it is reserved for severe chronic pain in patients who are intolerant of or refractory to systemic analgesics and to intrathecal morphine, and it requires implantation and lifelong management by a specialist pain service. There is no oral, injectable or transdermal route. Systemic administration causes severe hypotension because N-type channels also serve the sympathetic nervous system. Any material offered as ziconotide for non-intrathecal use would be both ineffective and dangerous.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Prescription-only medicine (POM), specialist pain service only. Licensed by the MHRA for the treatment of severe, chronic pain in adults who require intrathecal analgesia. Originally authorised centrally in the EU in February 2005. Administration requires an implanted or external intrathecal infusion system and is confined to specialist pain centres. |
| United States | FDA-approved (December 2004) for the management of severe chronic pain in adult patients for whom intrathecal therapy is warranted and who are intolerant of or refractory to other treatment. Carries a boxed warning for severe psychiatric symptoms and neurological impairment. |
| WADA (sport) | Not listed on the WADA Prohibited List. Ziconotide is a non-opioid analgesic and is not named in the S7 narcotics class, which lists specific opioids only. It is delivered by implanted intrathecal pump and has no plausible sporting application. |
Questions
Conus magus paralyses fish by injecting a cocktail of small, disulfide-braced peptides, each of which shuts down a specific ion channel with remarkable precision. Ziconotide is a synthetic copy of one of them, ω-conotoxin MVIIA, which happens to target the N-type calcium channel that pain-transmitting nerve terminals rely on to release their neurotransmitters. Its selectivity is the point: evolution optimised it to hit one channel and nothing else, which is very hard to achieve with a small molecule.
Two reasons. It does not cross the blood-brain barrier, so an injection into a vein or muscle never reaches the dorsal horn. And N-type calcium channels also operate in sympathetic nerves controlling blood vessels, so systemic exposure causes severe hypotension. Delivering it directly into cerebrospinal fluid via an implanted pump places tiny quantities exactly where they are needed while keeping systemic concentrations negligible.
No, and this is its main advantage. It has no activity at mu, delta or kappa opioid receptors. There is no tolerance requiring dose escalation over time, no physical dependence, no withdrawal syndrome and no respiratory depression. That makes it valuable for patients whose pain no longer responds to opioids or who cannot tolerate them. The trade-off is a substantial burden of neuropsychiatric side effects instead.
Neuropsychiatric effects dominate: confusion, hallucinations, psychosis, depression and suicidality have all been reported, and the US labelling carries a boxed warning. Cognitive impairment, memory loss, dizziness and ataxia are common and can take a couple of weeks to resolve after stopping. Creatine kinase elevation occurs frequently. Separately, the implanted delivery system carries its own risks including meningitis and catheter granuloma. Ziconotide is used only in specialist pain services with slow titration and regular psychiatric and cognitive review.